Avandia Panelist Issue Sent To HHS Inspector General

Law360, New York (July 27, 2010, 1:48 PM EDT) -- The U.S. Food and Drug Administration has asked the inspector general of the Department of Health and Human Services to look into concerns that one of its advisory panelists who voted to keep the controversial diabetes drug Avandia on the market is also a paid speaker for the drug's manufacturer.

The Wall Street Journal reported Tuesday that Dr. David Capuzzi, an endocrinologist from Philadelphia and a member of the FDA advisory committee that recently examined ongoing questions about Avandia is also a paid speaker for GlaxoSmithKline...
To view the full article, register now.